drugset / Trial / NCT06088004
Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors
Phase 1/2
Recruiting
218 enrolled
Suzhou Abogen Biosciences Co., Ltd.
Abogen Biosciences (Shanghai) Co., Ltd · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is an open-label, single-arm, dose-escalation, and dose-expansion clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ABO2011 monotherapy or in combination with Toripalimab in patients with advanced solid tumors.
Timeline
- Start
- 2023-09-28
- Primary completion
- 2026-12-30
- Completion
- 2027-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABO2011 | Messenger RNA (mRNA) | — | Other |
| Subject | Toripalimab | Monoclonal antibody | — | — |